West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$322.60 USD
-1.95 (-0.60%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $322.46 -0.14 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
West Pharmaceutical Services (WST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$415.14 | $470.00 | $355.00 | 28.69% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for West Pharmaceutical Services comes to $415.14. The forecasts range from a low of $355.00 to a high of $470.00. The average price target represents an increase of 28.69% from the last closing price of $322.60.
Analyst Price Targets (7 )
Broker Rating
West Pharmaceutical Services currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/1/2024 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
4/29/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/16/2024 | UBS | John N Sourbeer | Hold | Hold |
2/13/2024 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
2/7/2024 | Not Identified | Not Identified | Hold | Strong Buy |
10/26/2023 | William Blair | Matt Larew | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 8 |
Average Target Price | $415.14 |
LT Growth Rate | 7.30% |
Industry | Medical - Dental Supplies |
Industry Rank by ABR | 101 of 252 |
Current Quarter EPS Est: | 1.78 |